The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating clinical tools to monitor cardiovascular (CV) risk in men with localized high-risk or locally advanced prostate cancer (LHRPC) treated with hormone therapy (HT).
 
Neha Venkatesh
No Relationships to Disclose
 
Pankaj Chauhan
No Relationships to Disclose
 
Kabir Grewal
No Relationships to Disclose
 
Ana Aparicio
No Relationships to Disclose
 
Patrick Pilié
Consulting or Advisory Role - Novartis
Patents, Royalties, Other Intellectual Property - Biomarker
 
Sumit Subudhi
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Amgen; Apricity Health; Arcus Biosciences,; AstraZeneca; Baird; Bayer; Boxer Capital; Breaking Data; Bristol-Myers Squibb; Cancer Expert Now; ChemoCentryx; Clinical Comms Group; Dava Oncology; Dendreon; Hervolution Therapeutics; InProTher Janssen; Kahr Medical Ltd; Kiniksa; MacroGenics; MacroGenics; MD Education; Merck; Novartis; OncLive (owned by Intellisphere, LLC); Pfizer; Polaris; Portage Biotech; Regeneron; Rondo
Research Funding - AstraZeneca; Bristol-Myers Squibb; Janssen; Regeneron
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Regeneron
 
Paul Corn
Research Funding - Janssen Oncology (Inst)
 
Bilal Siddiqui
Research Funding - Regeneron (Inst)
 
Amado Zurita
Honoraria - Amedco; CancerNet; Janssen; McKesson
Consulting or Advisory Role - Bayer; Exelixis; Foundation Medicine; Hikma Pharmaceuticals; Pfizer
Research Funding - Advanced Biochemical Compounds; Astellas Pharma; Clarity Pharmaceuticals; Curium Pharma; Merck; Pfizer
Travel, Accommodations, Expenses - Hikma Pharmaceuticals; Janssen Oncology
 
Daniel Frigo
Employment - Biocity Biopharmaceuticals (I); Hummingbird (I)
Leadership - Biocity Biopharmaceuticals (I); Hummingbird (I)
Stock and Other Ownership Interests - ALMS Therapeutics (I); Barricade Therapeutics (I); Biocity Biopharmaceuticals (I); Hinova Pharmaceuticals (I); Hummingbird (I); MAIA Biotechnology (I)
Patents, Royalties, Other Intellectual Property - Frigo, D.E., A.R. Means and D.P. McDonnell. “CaMKK-? as a Target for Treating Cancer”. United States Patent 9999620. Issued 6/17/2018. “Novel Therapeutic Targets in the Androgen Receptor Signaling Pathway”. European Patent 2606130. Issued 3/13/2019.
 
Christopher Logothetis
Honoraria - AADi; Amgen; Boehringer Pharma GmbH; GlaxoSmithKline; Janssen Scientific Affairs
Research Funding - Aragon Pharmaceuticals (Inst); Janssen; Novartis (Inst); ORIC Pharmaceuticals (Inst)
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Efstratios Koutroumpakis
Research Funding - CPRIT; NIH/NCI
 
Andrew Hahn
Honoraria - Binacea; Kaplan Partners in Knowledge; Medscape
Consulting or Advisory Role - AVEO; Eisai; Exelixis; Intellisphere; Janssen Scientific Affairs; Pfizer
Research Funding - Bayer; Eisai (Inst)
Travel, Accommodations, Expenses - Dava Oncology